GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
Innovent’s Xinermei Intensifies Weight-Loss Drug Battle in China 
Netflix’s Bid for Warner Bros Discovery Aims to Cut Streaming Costs and Reshape the Industry 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
U.S. Reveals 2026 Medicare Star Ratings: Aetna, UnitedHealth Lead in Quality Scores 
Airline Loyalty Programs Face New Uncertainty as Visa–Mastercard Fee Settlement Evolves 
Visa to Move European Headquarters to London’s Canary Wharf 
RBI Cuts Repo Rate to 5.25% as Inflation Cools and Growth Outlook Strengthens 
Asian Currencies Edge Higher as Markets Look to Fed Rate Cut; Rupee Steadies Near Record Lows 
Asian Markets Mixed as Fed Rate Cut Bets Grow and Japan’s Nikkei Leads Gains 
Trump Hints at Major Autism Announcement, Raises Questions on Tylenol Link 
IMF Deputy Dan Katz Visits China as Key Economic Review Nears 
Momenta Quietly Moves Toward Hong Kong IPO Amid Rising China-U.S. Tensions 
Japan’s Nikkei Drops as Markets Await Key U.S. Inflation Data 
Asia’s IPO Market Set for Strong Growth as China and India Drive Investor Diversification 
European Oil & Gas Stocks Face 2026 With Cautious Outlook Amid Valuation Pressure 
Australia’s Economic Growth Slows in Q3 Despite Strong Investment Activity 
The World Health Organization is strongly recommending Pfizer's COVID-19 antiviral pill Paxlovid for patients with milder forms of the disease who were still at a high risk of hospitalization.
The WHO's experts declared in the BMJ medical journal that Pfizer's combination of nirmatrelvir and ritonavir was the preferable choice of treatment for unvaccinated, aged, or immunocompromised persons with Covid.
The WHO also gave a conditional recommendation" for the antiviral medication remdesivir, which was previously recommended against by the WHO for the same individuals.
Paxlovid was recommended by the WHO over Remdesivir, Merck's molnupiravir tablet, and monoclonal antibodies.
The WHO's experts said that Pfizer's oral therapy reduces hospitalization better than "existing alternatives," has fewer worries about hazards than molnupiravir, and is easier to administer than intravenous remdesivir and antibodies.
Paxlovid lowered the risk of hospital admission by 85 percent in two trials involving approximately 3,100 participants, according to the new recommendation.
The trials also indicated no significant difference in mortality and "little or no risk of treatment cessation due to side effects."
The advice is for anyone over the age of 18, but not for women who are pregnant or breastfeeding.
It also doesn't apply to people who have a low risk of disease consequences because the benefit would be insignificant.
Due to a paucity of data, WHO specialists also failed to provide an opinion for people with severe manifestations of the disease.
The WHO emphasized the limitations of antiviral medicines, noting that they can only be used when the disease is in its early stages.
This means people must test positive swiftly and be prescribed the tablet by a doctor, all of which, according to the WHO, might be a challenge for low- and middle-income nations.
However, the UN agency expressed "grave worry" that the disparities in access experienced with COVID vaccines will result in low- and middle-income countries being pushed to the back of the line once again.
Nonetheless, because Covid tablets may be administered at home rather than in a hospital, they have been hailed as a potentially game-changing advance in the fight against the pandemic.
Pfizer has agreed to let select generic drugmakers around the world to create cheaper copies of Paxlovid under a United Nations-backed system, after facing criticism for prioritizing wealthier countries with its vaccine.
The WHO, on the other hand, strongly advised Pfizer to allow other generic manufacturers to create the medicine and make it available faster and at more affordable costs.
